Publications by authors named "A Janssan"

Article Synopsis
  • CER-001 is an engineered HDL mimetic showing promise in reducing cholesterol and vascular inflammation, with a previous study indicating potential plaque regression in patients with high coronary plaque burden.
  • The objective of the latest study was to assess the effect of CER-001 infusions on coronary atherosclerosis progression in patients already on statins.
  • Conducted as a double-blind trial, 272 participants received either CER-001 or placebo over 10 weeks, focusing on changes in atheroma volume and overall safety.
View Article and Find Full Text PDF

Background And Aims: Little is known about the relation between serum lipid parameters and serial change in plaque composition using in vivo coronary imaging. The aim of this study was to examine the association between serum lipids and change in coronary plaque lipid burden assessed by near-infrared spectroscopy (NIRS).

Methods: We performed serial NIRS-intravascular ultrasound studies in 49 patients who underwent coronary angiography for an acute coronary syndrome (ACS) or stable ischemic symptoms.

View Article and Find Full Text PDF
Article Synopsis
  • High-density lipoprotein (HDL) has protective properties against heart disease, but effective treatments based on HDL are still under research; the CARAT trial aims to test a new HDL mimetic called CER-001 on patients following acute coronary syndrome (ACS).
  • In this phase 2 trial, 292 patients with significant atheroma volume will receive either CER-001 or a placebo through ten infusions over ten weeks, with assessments of their coronary artery condition before and after treatment.
  • The primary goal is to measure changes in atheroma volume and evaluate the safety and tolerability of CER-001, potentially offering a new way to treat atherosclerosis in at-risk patients.
View Article and Find Full Text PDF